Hangzhou Lianchuan Biotechnology

Hangzhou Lianchuan Biotechnology (LC-Bio), founded in 2006, operates as a global genomics technology company, providing advanced scientific research services and solutions. The company was established by overseas returnees, including Dr. Lang Qiulei, who currently serves as the Chairman and General Manager. The founding story involves a collaboration between professors and their student; Dr. Lang was a student of Professor Gao Xiaolian and Professor Zhou Xiaochuan at the University of Houston. Recognizing her capabilities, the professor couple invited her to lead the company's expansion into China. Zhou Xiaochuan acts as the Vice Chairman, and Gao Xiaolian is the Chief Scientist.

The firm's business is centered on high-throughput sequencing and bioinformatics technologies to serve clients in life sciences and medical research. Its customer base includes over 3,000 universities, hospitals, research institutions, and pharmaceutical companies worldwide. Revenue is generated by providing a comprehensive suite of services covering genomics, transcriptomics, proteomics, metabolomics, and epigenomics. The company operates on a model that starts with foundational, original technology and expands downstream to various commercial applications. This strategy has led to the development of products for the clinical application sector, including gene detection medical devices.

LC-Bio offers a wide array of services, including genome sequencing, single-cell sequencing, spatial transcriptomics, and multi-omics joint analysis. A key technological asset is the proprietary µParaflo® microfluidic gene in-situ synthesis platform. In 2015, the company developed the VariantPro™ gene capture technology, a one-step method for precisely capturing target genes. This has been foundational for developing several tumor multi-gene mutation detection kits. The company has also developed the VariantBaits™ liquid hybridization capture system, offering customized products to enterprise clients.

The company's history is marked by strategic technological shifts. Initially focusing on miRNA chips in 2006, it pivoted to high-throughput sequencing services in 2008. A significant milestone was achieved in 2017 when the company was listed on the New Third Board. The company has successfully completed multiple funding rounds, including an angel round in 2016, a Series A of 63.6 million RMB in 2017, a Series B of 115 million RMB in 2020, and a further strategic financing of nearly 100 million RMB in 2021. An IPO application was filed with the Sci-Tech Innovation Board (STAR Market) in 2022.

Keywords: genomics, high-throughput sequencing, bioinformatics, transcriptomics, proteomics, metabolomics, single-cell sequencing, spatial omics, gene capture technology, precision medicine, molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, µParaflo, VariantPro, DNA synthesis, life sciences research, clinical diagnostics, cancer genomics, multi-omics analysis